Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Paraganglioma × vandetanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Medullary 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Adenocarcinoma, Follicular 1

Interventions

lutetium Lu 177 dotatate 2 vandetanib 1 3-fluorobenzylguanidine 1 3-Iodobenzylguanidine 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡